| Kristen Selman, PT | |
|
355 Crossgates Blvd, Brandon, MS 39042-2602 | |
| (601) 825-3192 | |
| Not Available |
| Full Name | Kristen Selman |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | 355 Crossgates Blvd, Brandon, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235453598 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT4370 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kristen Selman, PT 355 Crossgates Blvd, Brandon, MS 39042-2602 Ph: () - | Kristen Selman, PT 355 Crossgates Blvd, Brandon, MS 39042-2602 Ph: (601) 825-3192 |
News Archive
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who test positive for SARS-CoV-2 and who are at high risk for progressing to severe COVID-19.
An experimental drug, LX211 (LUVENIQ-; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.
Three months after undergoing renal denervation —a procedure that delivers energy to overactive nerves leading to the kidney to decrease their activity—patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours compared with patients who underwent a sham procedure and experienced no major adverse effects, according to results from the SPYRAL-HTN OFF MED pivotal trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.
› Verified 4 days ago
Rashad Smith, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 107 Amethyst Ln, Brandon, MS 39047 Phone: 601-260-5767 | |
Drayer Physical Therapy Institute Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1220 N Shore Pkwy, Suite B, Brandon, MS 39047 Phone: 601-829-0505 Fax: 601-829-0506 | |
Mr. Mark Allen Livingston, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1220 N Shore Pkwy, Suite B, Brandon, MS 39047 Phone: 601-829-0505 Fax: 601-829-0506 | |
Sherry Teer Colson, DPT EDD Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 114 Northwind Dr, Brandon, MS 39047 Phone: 601-940-1090 | |
Dr. Avery Harps, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 289 Cornerstone Dr, Brandon, MS 39042 Phone: 601-706-4051 Fax: 601-706-4051 | |
Matthew Woodruff, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 359 Avalon Way, Brandon, MS 39047 Phone: 662-207-6756 | |
Mrs. Kitty Josette Stogner, PT, ATP Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 521 Pelahatchie Shore Dr, Brandon, MS 39047 Phone: 601-613-7328 |